Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Cetuximab in preoperative treatment of rectal cancer - term outcome of the XERT trial
Authors:ID Velenik, Vaneja (Author)
ID Ocvirk, Janja (Author)
ID Oblak, Irena (Author)
ID Anderluh, Franc (Author)
Files:.pdf PDF - Presentation file, download (332,74 KB)
MD5: 8459228AE348EEB862238B9C99B4A5AE
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Preoperative capecitabine-based chemoradiotherapy (CRT) is feasible for the treatment of resectable locally advanced rectal cancer (LARC). To try to improve efficacy, we conducted a phase II studz in which the epidermal growth factor receptor-targeting monoclonal antibody cetuximab was added to capecitabine-based CRT. The results for long-term survival and for an analysis investigating the relationship between survival and patient and disease characteristics, including tumour KRAS mutation status, and surgery type, are presented. Patients with resectable LARC received capecitabine (1250mg/m2 twice daily, orally) for 2 weeks followed by cetuximab alone (400 mg/m2 for 1 week) and then with CRT (250 mg/m2/week) comprising capecitabine (825 mg/m2 twice daily) and radiotherapy to the small pelvis (45 Gz in 25 1.8-Gz fractions), five dazs a week for five weeks. Surgery was conducted six weeks following CRT, with post-operative chemotherapy with capecitabine (1250 mg/m2 twice daily for 14 days every 21 days) three weeks later. Forty-seven patients were enrolled and 37 underwent treatment. Twenty-eight of the patients (75.7%) had T3N+ disease. Thirty-six patients were evaluable for efficacy. The median follow-up time was 39.0 months (range 5.0-87.0). The three-year local control, disease-free survival, relapse-free survival and overall survival rates were 96.9% (95% CI 90.0-100), 72.2% (57.5-86.9), 74.3% (95% CI 59.8-88.8) and 68.1% (95% CI 36.7-99.4), respectively. There was no significant association between survival and gender, age, tumour location in the rectum, type of surgery, pathological T or N status, tumour regression grade or tumour KRAS mutation status, although sample sizes were small. Preoperative cetuximab plus capecitabine-based CRT was feasible in patients with resectable LARC and was associated with an impressive three-year local control rate. The use of tumour KRAS mutation status as a biomarker for the efficacy of cetuximab-based regimens in this setting requires further investigation.
Publication status:Published
Publication version:Version of Record
Publication date:01.01.2012
Publisher:Association of Radiology and Oncology
Year of publishing:2012
Number of pages:str. 252-257, V
Numbering:Vol. 46, no. 3
Source:Ljubljana
PID:20.500.12556/DiRROS-18500 New window
UDC:616.35-006.6-08
ISSN on article:1318-2099
DOI:10.2478/v10019-012-0030-2 New window
COBISS.SI-ID:1362299 New window
Copyright:by Authors
Note:Soavtorji: Janja Ocvirk, Irena Oblak, Franc Anderluh;
Publication date in DiRROS:21.03.2024
Views:701
Downloads:138
Metadata:XML DC-XML DC-RDF
:
VELENIK, Vaneja, OCVIRK, Janja, OBLAK, Irena and ANDERLUH, Franc, 2012, Cetuximab in preoperative treatment of rectal cancer - term outcome of the XERT trial. Radiology and oncology [online]. 2012. Vol. 46, no. 3, p. 252–257, v. [Accessed 11 April 2025]. DOI 10.2478/v10019-012-0030-2. Retrieved from: https://dirros.openscience.si/IzpisGradiva.php?lang=eng&id=18500
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol. oncol.
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 New window

Secondary language

Language:Slovenian
Title:Predoperativna radioterapija, kapecitabin in cetuksimab pri zdravljenju lokalno napredovalnega raka danke
Keywords:novotvorbe danke, radioterapija, mutacije, preživetje, bolniki


Back